Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ps Therapy Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner and 1 distinct art unit. The limited volume of pending actions suggests a targeted filing strategy or a specific phase of portfolio development. Practitioners should focus on the specific technical standards of this 1 distinct art unit to ensure the application progresses efficiently through the USPTO.
The busiest examiner for this portfolio is PALLAY, MICHAEL B, who is currently managing 1 pending office action. This represents the total pending workload for the company, as the busiest examiner pending count of 1 matches the total pending office actions of 1. Because the prosecution is concentrated under 1 distinct examiner, the outcome for this technology area is currently tied to a single review process. Practitioners should monitor the specific requirements of PALLAY, MICHAEL B to ensure efficient progress for this pending application. Navigating the Biotechnology & Pharmaceuticals area effectively requires a tailored approach to this examiner's history.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PALLAY, MICHAEL B | 1 | 55.8% | +34.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18295520 | CONTACT LENS COMPOSITIONS AND METHODS OF USE THEREOF | PALLAY, MICHAEL B | 87d overdue |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18295520 | CONTACT LENS COMPOSITIONS AND METHODS OF USE THEREOF | PALLAY, MICHAEL B | 1617 | §103 | Non-Final OA | 87d overdue | Pending | Apr 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial